| __timestamp | HUTCHMED (China) Limited | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 26684000 | 49315000 |
| Thursday, January 1, 2015 | 29829000 | 75043000 |
| Friday, January 1, 2016 | 39578000 | 83749000 |
| Sunday, January 1, 2017 | 43277000 | 122682000 |
| Monday, January 1, 2018 | 48645000 | 207761000 |
| Tuesday, January 1, 2019 | 52934000 | 284812000 |
| Wednesday, January 1, 2020 | 61349000 | 317875000 |
| Friday, January 1, 2021 | 127125000 | 282660000 |
| Saturday, January 1, 2022 | 136106000 | 451421000 |
| Sunday, January 1, 2023 | 133175999 | 481871000 |
Unleashing insights
In the competitive world of biotechnology, managing operational expenses is crucial for sustainable growth. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Sarepta Therapeutics, Inc. and HUTCHMED (China) Limited from 2014 to 2023. Over this period, Sarepta's SG&A expenses surged by approximately 878%, reflecting its aggressive expansion and investment in research and development. In contrast, HUTCHMED's expenses grew by about 399%, indicating a more measured approach.
Sarepta's expenses peaked in 2023, reaching nearly 482 million, a testament to its rapid scaling efforts. Meanwhile, HUTCHMED's expenses also saw a significant rise, peaking at around 136 million in 2022. This divergence in spending strategies highlights the different growth trajectories and market strategies of these two biotech firms. Investors and stakeholders should consider these trends when evaluating the companies' future potential.
Who Optimizes SG&A Costs Better? Zoetis Inc. or Sarepta Therapeutics, Inc.
Comparing SG&A Expenses: Takeda Pharmaceutical Company Limited vs Sarepta Therapeutics, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Sarepta Therapeutics, Inc. or Evotec SE
CRISPR Therapeutics AG or HUTCHMED (China) Limited: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Veracyte, Inc. and HUTCHMED (China) Limited
Selling, General, and Administrative Costs: MorphoSys AG vs HUTCHMED (China) Limited
Cost Management Insights: SG&A Expenses for Vericel Corporation and HUTCHMED (China) Limited
Operational Costs Compared: SG&A Analysis of Catalyst Pharmaceuticals, Inc. and HUTCHMED (China) Limited
HUTCHMED (China) Limited vs ImmunityBio, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: HUTCHMED (China) Limited vs Amphastar Pharmaceuticals, Inc. Trends and Insights
HUTCHMED (China) Limited or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of HUTCHMED (China) Limited and Viridian Therapeutics, Inc.